StockNews.com Downgrades Agenus (NASDAQ:AGEN) to Sell

StockNews.com downgraded shares of Agenus (NASDAQ:AGEN) from a hold rating to a sell rating in a research report report published on Monday.

A number of other equities research analysts have also recently commented on AGEN. William Blair cut Agenus from an outperform rating to a market perform rating in a report on Thursday, July 18th. HC Wainwright downgraded shares of Agenus from a buy rating to a neutral rating and dropped their target price for the stock from $40.00 to $9.00 in a research report on Thursday, July 18th. Jefferies Financial Group reaffirmed a hold rating and issued a $7.00 target price (up previously from $3.00) on shares of Agenus in a research report on Friday, July 19th. Baird R W cut Agenus from a strong-buy rating to a hold rating in a research note on Friday, July 19th. Finally, Robert W. Baird downgraded shares of Agenus from an outperform rating to a neutral rating and dropped their target price for the stock from $35.00 to $8.00 in a research report on Friday, July 19th. One analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the stock. According to MarketBeat, Agenus presently has a consensus rating of Hold and an average target price of $10.50.

Agenus Stock Up 12.9 %

NASDAQ:AGEN opened at $5.17 on Monday. The company has a fifty day simple moving average of $11.35 and a two-hundred day simple moving average of $11.84. Agenus has a 52 week low of $4.41 and a 52 week high of $32.00. The company has a market cap of $108.56 million, a price-to-earnings ratio of -0.40 and a beta of 1.33.

Agenus (NASDAQ:AGEN) last released its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($2.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.33) by ($1.19). The business had revenue of $23.51 million for the quarter, compared to the consensus estimate of $64.73 million. During the same period in the previous year, the company earned ($4.00) EPS. On average, analysts expect that Agenus will post -10.73 EPS for the current year.

Hedge Funds Weigh In On Agenus

A number of hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC grew its position in Agenus by 526.6% in the fourth quarter. SG Americas Securities LLC now owns 198,735 shares of the biotechnology company’s stock worth $165,000 after acquiring an additional 167,017 shares in the last quarter. Cardinal Strategic Wealth Guidance increased its position in Agenus by 28.2% during the fourth quarter. Cardinal Strategic Wealth Guidance now owns 910,265 shares of the biotechnology company’s stock worth $754,000 after buying an additional 200,000 shares during the last quarter. Powell Investment Advisors LLC acquired a new position in Agenus during the fourth quarter worth $166,000. Los Angeles Capital Management LLC raised its holdings in Agenus by 95.3% during the fourth quarter. Los Angeles Capital Management LLC now owns 200,812 shares of the biotechnology company’s stock valued at $166,000 after buying an additional 97,992 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Agenus in the fourth quarter worth about $95,000. Institutional investors and hedge funds own 61.46% of the company’s stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.